Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by
SpePharm

Two MuGard US Patents Issued

DALLAS, June 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC
Bulletin Board: ACCP), announced today that its European partner, SpePharm has
commenced commercial launch of MuGard in Greece. This follows previous
commercial launches in Germany, Italy and the UK. Under a license from Access
Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory
approval and commercialization in the 27 countries of Europe. SpePharm plans
to launch MuGard in the rest of Europe over the coming 12 to 18 months. The
license agreement includes royalties on net sales to Access.

Additionally, the Company announced that two MuGard(TM) patents have been
issued from the United States Patent and Trademark Office, as US Patent
numbers 7,544,348 and 7,547,433. The second patent includes claims on
formulations with actives against mucocutaneous disorders, which provides
protection of product line extensions.

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the
management of oral mucositis, a debilitating side effect of many anticancer
treatments. Up to 40% of all patients receiving chemotherapy and/or
radiotherapy develop moderate to severe mucositis, and almost all patients
receiving radiotherapy for head and neck cancer and those undergoing stem cell
transplantation develop mucositis. Updated clinical practice guidelines for
the prevention and treatment of mucositis recommend the use of a preventive
oral care regimen as part of routine supportive care along with a therapeutic
oral care regimen if mucositis develops. The market for the treatment of oral
mucositis is estimated to be in excess of $1 billion world-wide.

MuGard forms a protective coating over the oral mucosa when swirled gently
around the mouth. In a comparison of cancer patients receiving standard
mucositis care with those patients receiving MuGard, the incidence and
severity of mucositis was significantly lower in the MuGard treated group
using a validated scale for the assessment of oral mucositis.

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that
develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include ProLindac(TM),
currently in Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The company also has
other advanced drug delivery technologies including Cobalamin(TM)-mediated
targeted delivery and oral drug delivery, its proprietary nanopolymer delivery
technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a
humanized monoclonal antibody which acts as an anti-angiogenesis factor and is
targeted to breast cancer; and Thiarabine, a new generation nucleoside analog
which has demonstrated both pre-clinical and clinical activity in certain
cancers. For additional information on Access Pharmaceuticals, please visit
our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements include those relating to:
clinical trial plans and timelines and clinical results for ProLindac and
product candidates acquired in the MacroChem transaction, our ability to
execute licensing agreements in the future, Access' plans to continue and
initiate clinical trials, the value of its products in the market (including
MuGard and the size of the overall market for mucositis products), its ability
to achieve clinical and commercial success and its ability to successfully
develop marketed products. These statements are subject to numerous risks,
including but not limited to Access' need to obtain additional financing in
order to continue the clinical trial and operations and to the risks detailed
in Access' Annual Reports on Form 10-K and other reports filed by Access with
the Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.

Stephen B. Thompson, Vice President, Chief Financial Officer of Access
Pharmaceuticals, Inc., +1-214-905-5100; Investor Relations: Donald C.
Weinberger or Diana Bittner (media) of Wolfe Axelrod Weinberger Assoc. LLC,
+1-212-370-4500, for Access Pharmaceuticals, Inc.